

CERTIFICATE OF EFS TRANSMISSION		
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted to the United States Patent and Trademark Office on the date shown below via the "Electronic Filing System" in accordance with 37 C.F.R. § 1.6(a)(4).		
Alana Kriegsman	/Alana G. Kriegsman/	October 30, 2007
Type or print name	Signature	Date

**In The United States Patent And Trademark Office**

**Applicants:** MABIRE, Dominique Jean-Pierre et al.      **Art Unit:** 1624  
**Serial No.:** 10/596,086      **Examiner:** Tucker, Zachary C.  
**Filed:** 05/30/2006      **Confirmation Number:** 1676  
**For:** 6-SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE) POLYMERASE INHIBITORS

Mail Stop: Patent Application (SRR)  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR RESTRICTION REQUIREMENT  
Pursuant to Rule 37 C.F.R. § 1.142(c)**

Dear Sir:

Applicant requests that the above-captioned application be restricted in the manner presented below.

- ☒ Suggested Restriction Requirement begins on 2 of this paper.
- ☐ Amendments to the Specification begin on page      of this paper.
- ☒ Amendments to the claims are reflected in the listing of the claims that begins on page      of this paper.
- ☐ Amendments to the Drawings begin on page      of this paper and include an attached replacement sheet.
- ☒ Conclusion Remarks begin on 14 of this paper.

**SUGGESTED RESTRICTION REQUIREMENT**

Applicant requests that the above-captioned application be restricted in the manner suggested below:

- Group I:** Compounds according Formula I as currently exemplified in claims 1-4
- Group II:** Pharmaceutical compositions of the compounds of Formula I as currently exemplified in claims 6 and 14-16
- Group III:** Methods of treatment and prevention of a PARP mediated disorders using the compounds of Formula I as exemplified in claims 8, 17, 20 and 23
- Group IV:** Methods for enhancing the effectiveness of chemotherapy using the compounds of Formula I as exemplified in claims 10, 18, 21 and 24
- Group IV:** Methods for enhancing the effectiveness of radiotherapy using the compounds of Formula I as exemplified in claims 11, 19, 22 and 25
- Group V:** Combinations of chemotherapeutic agents and compounds of Formula I as exemplified in claims 12 and 26-28
- Group VI:** Processes of making compounds of Formula I and products and pharmaceutical compositions made by such processes as exemplified in claims 13, 29 and 30

In the event that the Examiner accepts Applicant's suggested restriction requirement, Applicant elects without traverse Group I, with claims 1-4 reading on Group I, and withdraws the remaining claims from consideration as being drawn to non-elected groups.

In the event that the Examiner requests for search purposes election of the species within the elected group, Applicant elects the following species that reads on the elected group:

Compound 1 of claim 4.

In compliance with new rule 37 C.F.R. § 1.75, the claims elected for initial prosecution (Group I, claims 1-4) include 2 independent claims and 2 dependent claims.